The Employers’ Guide to GLP-1s

  • White Paper
  • Noom Weight

Summary

As the demand for GLP-1s continues to surge, it’s no surprise they’re now among the top-cost drugs for employers. In this white paper, learn everything you need to know about GLP-1s to guide your obesity care strategy.

Ozempic and Mounjaro side effects

Breakthrough anti-obesity medications called GLP-1s have revolutionized the treatment landscape for obesity. While these medications have proven effective, they can be costly. If just half of those eligible sought GLP-1s for weight loss, prescription costs could increase by more than $840 per member per year across the entire population. Now more than ever before, employers need a proactive GLP-1 strategy to eliminate unnecessary spend, while optimizing health outcomes.  

In this white paper, you’ll discover:

  • The latest evidence behind GLP-1s
  • Why GLP-1s may not be for everyone
  • The importance of a multidisciplinary, stepped care approach to sustain long-term health outcomes and control costs

Download the White Paper

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Related Content

  • Blog
  • Noom Med
  • August 15
  • 2 min read

Noom Med Offers Employers a Cost-Effective Solution for Weight Loss Drugs

Demand for weight loss medications is surging and employers are tasked with finding cost-effective solutions for employees seeking sustainable weight loss and obesity solutions. Noom Med’s program helps employees achieve sustained weight loss while lowering healthcare costs for employers

By Noom Team
  • Blog
  • GLP-1s
  • August 15
  • 1 min read

Employer Strategies for Maximizing the Promise of GLP-1s

The numbers are clear: 160 million adults in the U.S. want to improve their health and well-being through weight loss. As many employers already know, adding obesity management programs to health benefit plans can boost employee motivation and health outcomes. For those who are affected, reducing weight by just 5-10% can improve risk factors and […]

By Noom Team
  • Blog
  • August 15
  • 1 min read

From Weight Loss to Risk: Understanding GLP-1’s Impact on Eating Disorders

Weight loss medication abuse is not new. Diet pills, caffeine, laxatives, and others have been around for a long time, but with the emergence of GLP-1s, more reports of disordered eating have surfaced. While these drugs have helped millions of individuals reach their weight loss goals, many suffer side effects that ultimately lead them to discontinue use, resulting not only in money lost, but weight regain. In this post, we'll deep dive into the discussion around GLP-1s and eating disorders, to ensure that employers, providers and health plans have access to the right support for members on GLP-1s.

By Noom Team

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.

REQUEST DEMO